ACADIA Pharmaceuticals Inc. (ACAD)

43.89
0.65 1.50
NASDAQ : Health Technology
Prev Close 43.24
Open 43.18
Day Low/High 43.18 / 43.33
52 Wk Low/High 14.01 / 44.85
Volume 23.90K
Avg Volume 2.29M
Exchange NASDAQ
Shares Outstanding 150.74M
Market Cap 6.02B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Some Midday Observations

"Every little swallow, every chick-a-dee Every little bird in the tall oak tree The wise old owl, the big black crow Flappin' their wings signin' "go bird, go" Rockin' robin, (tweet-tweet-tweet) Rock-rock-rockin' robin' (tweet-tweedilly-tweet) Go ro...

The Good, the Bad and the Ugly (Mid-Afternoon Edition)

"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have to prepare for my Tulane trip. So let's move to the abbreviated Monarc...

Takeaways and Observations (Early Edition)

'Til April in Paris, chestnuts in blossom Holiday tables under the trees April in Paris, this is a feeling That no one can ever reprise - April in Paris, Vernon Duke and Yip Harburg - (rare video with Ella Fitzgerald!)  The market gapped higher and ...

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

I'm Big on Housing Entering Quarter No. 2

I'm Big on Housing Entering Quarter No. 2

Home builders make up the second-largest allocation in my portfolio, behind biotech.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

What Poker Taught Me About Investing

What Poker Taught Me About Investing

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

Takeaways And Observations

For the first time in six years the DJIA fell for the eighth consecutive day. That said the Nasdaq has risen in ten of the last thirteen trading sessions as Donald Trump may be making volatility and uncertainty great again. (For that divergence and ...

Takeaways & Observations

Risk happens fast.  Most don't short and shouldn't short -- it's a game that requires volumes of risk control.  However, I would continue to maintain well above-average cash positions.  Today was not a benign event, in my view.  Nor was it likely a ...

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Welcome to the Small-Cap Biotech Mailbag!

Welcome to the Small-Cap Biotech Mailbag!

We answer recent reader questions about three of the biotech stocks we regularly cover.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

My Takeaways and Observations

The market pushed back presumably after it digested the inaugural speech and absorbed the marches around the world.   I don't believe the new president will be market and economy friendly.    The reflation trade is in question today.  And I remain b...

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

My Takeaways and Observations

I have a series of meetings this afternoon and tomorrow morning so I want to get "Takeaways" out early today. I started with what I think is an important opening missive, "Wary in an Uncertain World" in which I covered a number of bases. I truly bel...

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

3 Biotechs Screaming 'Takeover Target'

3 Biotechs Screaming 'Takeover Target'

M&A activity should perk up substantially in the small and mid-cap space this year.

My Takeaways and Observations

"Who you tryin' to get crazy with, 'ese? Don't you know I'm loco?..." -- Cypress Hill, Insane in the Brain 2017 will be the year of "The Dude."    My favorite large-cap long Allergan  and short Caterpillar   for next year.  AGN closed up by $4(!) wh...

My Takeaways and Observations

More of the same -- as Mr. Market remains enthusiastic with The Orange Swan and his contemplated policies aimed at catalyzing domestic economic growth.   But, with fear and doubt having left Wall Street, we may be reaching The Outer Limits. And I ha...

Acadia Pharmaceuticals Soars After Positive Alzheimer's Disease Study

Acadia Pharmaceuticals Soars After Positive Alzheimer's Disease Study

Shares of Acadia jumped Tuesday after the bio-pharmaceutical company reported positive results for a drug used for Alzehimer's patients.

My Takeaways and Observations

Slow day, at meetings all morning.   Despite the strength in our currency (and its adverse implications on multi-national profitability), there was no follow-through to yesterday's schmeissing.   I reflected on my July call that we have hit a Genera...

Takeaways and Observations

The markets moved lower from the "get go," though about the time Sixty Minutes was on last evening the S&P 500 futures were up 10 handles. (Futures closed down 2.5 handles)   Perhaps this is the start of a well due correction. Apropos, here is the q...

My Takeaways and Observations

What a strange day -- maybe even ominous.   This table tells it all.    The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

The Good, the Bad and the Ugly

"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly" The Good, the Bad and the Ugly" I further added to my short exposure today in a quiet, pre-Thanksgiving trading session. And now it's time to run down "The Good...

The Good, the Bad and the Ugly (2:30 PM Edition)

"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly "The Good, the Bad and the Ugly" I did only a small amount of trading today (and added to short exposure), and there will be no "Takeaways" today (it's family ti...